This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac troponin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California).
Background
Studies on patients with acute coronary syndromes and on seemingly healthy subjects have shown that even very minor elevations of cardiac troponins are associated with an increased risk of death. However, the normal plasma levels of cardiac troponins are still not known.
Methods
cTnI plasma levels were measured in 542 healthy subjects, 319 men (age 59.9 Ϯ 11.8 years) and 213 women (age 59.8 Ϯ 13.1 years), and in 1,503 randomly selected patients of the GUSTO IV (Global Utilization of Strategies To open Occluded arteries IV) cohort with unstable angina and non-ST-segment elevation myocardial infarctions (MIs).
Results
The cTnI levels at 10% coefficient of variation and 20% coefficient of variation imprecision were 0.0033 and 0.0016 g/l, respectively. The cTnI levels were measurable in Ͼ95% of the healthy subjects. The median level of healthy subjects Ͻ60 years of age was 0.0032 g/l (range 0.0011 to 0.0079 g/l) with the 99th percentile being 0.010 g/l. No sex differences were observed. A receiver-operator characteristic curve analysis showed an optimal discrimination between healthy subjects and patients at 0.0064 g/l with a sensitivity of 84.8% (95% confidence interval: 82.8% to 86.6%) and specificity of 89.7% (95% confidence interval: 86.8% to 92.2%). Outcomes as to death and/or MI were significantly different at this level (p Ͻ 0.01) in the GUSTO IV cohort.
Conclusions
The novel high-sensitivity cTnI prototype assay from Beckman Coulter allows for the first time the measurement of cTnI levels in almost all healthy subjects. Our data indicate that the assay may be a powerful aid in the diagnosis and outcome prediction of patients with suspected myocardial ischemia and question any definition of myocardial infarction. The assay of blood levels of cardiac troponins has become the recommended procedure for the detection of cardiac injury in patients with the acute coronary syndrome (ACS) and acute myocardial infarction (AMI) (1) . Elevated levels, however, may also be seen in subjects without apparent signs of cardiovascular disease and are in these cases important predictors of future episodes of AMI and/or premature death in cardiovascular disease (2, 3) . As recommended by the consensus documents, cardiac troponins should be See page 1173 measurable at the 99th percentile of the upper reference limit (URL) in healthy subjects with a maximum imprecision of 10% coefficient of variation (CV) (4, 5) , a requirement currently only met by a few available assays. In previous reports we showed that the 99th percentile is age dependent, because elderly subjects in many cases had signs of elevated levels above those of younger subjects, suggesting ongoing subclinical processes in a portion of seemingly healthy subjects (6) . Thus, the proper definition of the 99th percentile URL is extremely difficult and very much dependent on the study cohort.
Recent developments and improvements of cardiac troponin assays have clearly indicated that subjects with even very minor elevations of cardiac troponins are at increased risk of premature AMI and/or death (3, (7) (8) (9) . Thus, the more sensitive the assay is, the more patients are identified at risk. The open question therefore remains, "How sensitive should a cardiac troponin assay be?" This question will only be answered with a cardiac troponin assay that is able to measure any elevations with acceptable imprecision, and to identify such elevations it is necessary to know what the normal levels of cardiac troponins are. In this report we show the results of such a development, as the recent prototype cardiac troponin I (cTnI) assay by Beckman Coulter is able to identify troponin I levels in virtually all healthy subjects, and this assay allows us to define the discrimination between healthy subjects and those with ACS with high accuracy.
Patients and Methods
Patients. The GUSTO IV (Global Utilization of Strategies To open Occluded arteries IV) trial included 7,800 patients with non-ST-segment elevation ACS from 458 centers in 24 countries during 1999 and 2000 (10, 11) . The detailed design and main results of the trial have been published. Eligible patients were Ն21 years of age with 1 or more episodes of angina lasting Ն5 min, within 24 h of admission and either a positive cardiac troponin T (cTnT) or cTnI test (above the upper limit of normal for the local assay) or Ն0.5 mm of transient or persistent ST-segment depression. The study was conducted in a double-blind fashion with patients randomly assigned to 3 treatment groups: abciximab infusion for 24 or 48 h or corresponding placebo infusion. All patients received aspirin, 150 to 325 mg orally daily, for long-term treatment as well as either unfractionated heparin infusion for 48 h (n ϭ 6,826) or subcutaneous dalteparin every 12th hour for 5 to 7 days (n ϭ 974). Coronary angiography was not to be performed during or within 12 h after the completion of study agent infusion. For this study we selected random serum samples from a cohort of 1,503 patients.
The study on healthy subjects consisted of 537,388 men (median age 62 years, range 28 to 76 years) and 213 women (median age 64 years, range 29 to 76 years), of which 42 subjects were above the age of 75 years; 384 of the subjects were included in the SWISCH (Sweden Women and Men and Ischemic Heart Disease) study during 2000 to 2001 and 153 were included in a cohort of healthy employees. Employees were included if found healthy after a general physical examination by a physician, a normal electrocardiogram at rest, and a questionnaire-based survey of previous and present disease that did not indicate any health problems. The SWISCH study was a case-control study of risk factors for coronary artery disease in older men and women (12) . In this study, subjects were randomly recruited from the population using the population registry and matched for age and sex with patients with unstable coronary artery disease included at 6 hospitals in the FRISC II (Fragmin and Fast Revascularisation during Instability in Coronary artery disease) trial during 1996 to 1998. Details of these studies were published previously (13, 14) . The FRISC II and GUSTO IV trial populations were strikingly similar (15, 16) .
The imprecision profile of the assay was estimated from the analysis of duplicate samples of 306 patients admitted to the emergency department with suspicion of cardiac disease. The samples were leftover plasma and were analyzed without knowledge of the identity or diagnosis of the patients. The procedure was approved by the local ethics committee.
Methods
The cTnI assay was a prototype assay supplied by Beckman Coulter and was run on the Access instrument (Beckman Coulter, Fullerton, California) (17) . Levels Ͼ10 g/l were not further analyzed but assigned the value of 10 g/l. The AccuTnI assay was run on the Access instrument according to instructions of the manufacturer. Statistics. Passing-Bablok regression analysis, MannWhitney nonparametric test for group comparisons, chisquare test, and receiver-operator characteristic (ROC) curve analysis were used. The imprecision profile of the Access high-sensitivity troponin I assay was estimated using the Sadler and Smith method (18) . In brief, a 3-parameter relationship between variance of the replicate measurements of cTnI with the high-sensitivity cTnI assay and their mean concentrations was estimated using unweighted nonlinear least-squares regression. Outliers were identified as samples that were either 3 times higher or 3 times lower than the interquartile levels of the whole reference population (19) . In PassingBablok regression analysis, only results Ͻ10 g/l were included. All calculations were made by the statistical software Medcalc version 9 (Mariakerke, Belgium) and Statistica for Windows version 8 (Tulsa, Oklahoma). 
Results
The imprecision profile, based on CVs of assaying duplicate samples of 306 consecutive patients with suspicion of cardiac disease, showed an estimated 10% CV at 0.0033 g/l and an estimated 20% CV at 0.0016 g/l (Fig. 1 ).
Overall the high-sensitivity cTnI assay was significantly correlated to the AccuTnI assay, r 2 ϭ 0.88 (p Ͻ 0.001) (n ϭ 1,343 GUSTO IV samples). A Passing-Bablok regression analysis showed high-sensitivity cTnI ϭ Ϫ0.01566 ϩ 0.6372 AccuTnI with a significant deviation from linearity.
The cTnI levels in the cohort of seemingly healthy subjects are shown in Figure 2 and indicate that 93% of all samples had levels above the 20% CV cutoff of 0.0016 g/l and 50% above the 10% cutoff of 0.0033 g/l. The majority of results formed a bell-shaped distribution, with 93% of the results being Ͻ0.010 g/l. With all results from the reference samples included, the 99th and 97.5th percentiles were 0.064 and 0.029 g/l, respectively. After outlier exclusions the 97.5th and 99th percentiles were found at 0.0110 and 0.0144 g/l, respectively. For the cohort Ն60 Venge et al. September 22, 2009 September 22, :1165 High-Sensitivity cTnI Access Prototype Assay years of age, the 97.5th and 99th percentiles were 0.012 and 0.019 g/l, respectively, and for the cohort Ͻ60 years of age were 0.009 and 0.010 g/l, respectively (Fig. 3) . No sex differences were observed in either of these 2 age cohorts (Fig. 3) . For the whole cohort, no age difference was found, whereas among those subjects who had levels Ն0.010 g/l, 75% were older than 60 years, as compared with 56% in the cohort with levels Ͻ0.010 g/l (p ϭ 0.03).
In the analysis of a subset of the GUSTO IV cohort, the results showed significantly elevated levels as compared with the healthy subjects (p Ͻ 0.001) (Fig. 4) . Twenty percent of the GUSTO IV subjects had levels below 0.010 g/l. An ROC curve analysis including all results from the healthy cohort showed an area under the curve (AUC) of 0.942 (95% confidence interval [CI]: 0.931 to 0.952) with a sensitivity and specificity in the discrimination between ACS and healthy subjects of 88.4% (95% CI: 86.6% to 89.9%) and 85.0% (95% CI: 81.7% to 87.9%), respectively, at the optimal cutoff of 0.0064 g/l (Fig. 5) . After outlier exclusion, the AUC increased marginally to 0.948 (not significant). Adopting the 99th percentile cutoffs after outlier exclusion, that is, 0.01 g/l and 0.019 g/l for those Ͻ60 years old and for the whole cohort, respectively, the specificities increased substantially to 95.2% and 99.1%, respectively ( Table 1) .
The GUSTO IV study protocol does not allow the distinction between patients with non-ST-segment elevation myocardial infarction (MI) and unstable angina. As a surrogate marker for this distinction, we therefore used cTnT with a cutoff of 0.03 g/l, corresponding to the 10% CV level for the third-generation TnT assay on an Elecsys 2010 (kit insert, Roche Diagnostics, Basel, Switzerland). We found that 63.1% of the patients had cTnT levels Ն0.03 g/l and 71.2% of the patients had cTnI levels Ն0.017 g/l (Ն99th percentile for the healthy subjects). Figure 6 shows the distribution of cTnI levels in these 2 subsets as compared with the healthy reference. The cTnI levels were 4-fold and significantly elevated in the subset with cTnT The 99th and 97.5th Percentile Levels of cTnI in Seemingly Healthy Subjects (A) Data from subjects Ͻ60 years of age and divided by sex. (B) Data from subjects Ն60 years of age and divided by sex. No statistical differences between sexes were found in either of the 2 cohorts. The percentile levels were defined after exclusion of outliers. In subjects Ͻ60 years of age results Ͼ0.012 g/l and in subjects Ն60 years of age results Ͼ0.028 g/l were defined as outliers. Abbreviations as in Figure 1 . The difference in cTnI levels between the cohorts was highly significant (p Ͻ 0.0001). ACS ϭ acute coronary syndrome; other abbreviations as in Figure 1 .
Ͻ0.03 g/l (p Ͻ 0.001). The cTnI levels in the subset with elevated cTnT levels were on average more than 500-fold increased. Figure 7 shows the ROC curve analysis of the 2 subsets and the diagnostic distinction from healthy subjects. In the subset with nonelevated cTnT, the AUC was 0.848 (95% CI: 0.825 to 0.869). The optimal cutoff was 0.0046 g/l, with a corresponding sensitivity and specificity of 79.5% (95% CI: 75.8% to 82.8%) and 76.0% (95% CI: 72.2% to 79.6%), respectively. The positive likelihood ratio was 3.31 (95% CI: 3.1 to 3.5), and the negative likelihood was 0.27 (95% CI: 0.2 to 0.3). In the subset with elevated cTnT, the AUC was 0.996 (95% CI: 0.991 to 0.999). The optimal cutoff was 0.0164 g/l with a corresponding sensitivity and specificity of 98.7% (95% CI: 97.8% to 99.4%) and 96.3% (95% CI: 94.4% to 97.7%), respectively. The positive likelihood ratio was 26.8 (95% CI: 26.3 to 27.2), and the negative likelihood ratio was 0.013 (95% CI: 0.006 to 0.03).
Patient outcomes regarding death in 1 year or the composite end point of death and/or MI within 30 days is shown in Table 2 . In total, 110 deaths in 1 year and 106 deaths and/or MI were observed in the cohort. No events were seen below the median levels for healthy subjects and 4 and 6 events, respectively, below the optimal cutoff of 0.0064 g/l (p ϭ 0.001 and p ϭ 0.01, respectively). At higher cutoffs, the number of events below the respective cutoff increased gradually, but were still significantly lower even at the highest cutoff of 0.019 g/l (p ϭ 0.004 and p ϭ 0.007).
Discussion
The prototype cTnI assay used in this report was shown to have a sensitivity sufficient to measure cTnI levels in almost all healthy subjects. Thus, for the first time we have been able to define normal levels and have shown that they essentially follow a Gaussian distribution. By this assay we Receiver-operator characteristics (ROC) curve analysis of the discrimination of healthy subjects and subjects with the acute coronary syndrome (GUSTO IV). The ROC curve and 95% confidence interval are shown, as well as the sensitivity and specificity at the optimal discrimination level 0.0064 g/l. Abbreviations as in Figures 1 and 4 .
The Diagnostic Discrimination Between Seemingly Healthy Subjects and Patients With the Acute Coronary Syndrome (GUSTO IV) at Different Cutoff Levels of the High-Sensitivity cTnI Access Assay The comparison of cTnI levels in seemingly healthy subjects and in patients with the acute coronary syndrome (GUSTO IV) with cardiac troponin T (cTnT) below or above 0.03 g/l. Results above 10 g/l were assigned 10 g/l. The difference in cTnI levels between the cohorts was highly significant (p Ͻ 0.0001) (analysis of variance) as were the differences between healthy subjects and either of the 2 GUSTO IV subsets (p Ͻ 0.0001). Abbreviations as in Figures 1 and 4 .
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High-Sensitivity cTnI Access Prototype Assay also have shown that men and women have equal levels and that the levels were independent of age. The only apparent age and sex differences were related to the fact that outliers were overrepresented in the elderly cohort and in particular among men. This may be a reflection of subclinical disease in some subjects with chronic myocardial injury and is not unexpected considering the fairly advanced age of the reference population. Slight cTnI elevations were previously found in a cohort of seemingly healthy 70-year-old men and were shown to be related to premature death in cardiovascular disease (3) . We also found that subjects with documented signs and symptoms of myocardial ischemia, also when not fulfilling the current definition of AMI (i.e., cTnT Ͼ0.03 g/l), had on average significantly higher levels than seemingly healthy subjects and that the event rates regarding death and MI were related to the cTnI levels even at very low levels. We defined the functional sensitivity of the cTnI by means of the imprecision profile derived from the CVs of duplicate measurements of consecutive samples of patients with suspicion of cardiac disease obtained from our emergency department. The 10% and 20% CVs obtained from these results are extrapolated estimates because these CVs were not exceeded at any cTnI concentration. However, the reasonably correct estimates of the levels obtained were supported by the distribution profile of the levels of the reference samples because these also showed a harmonious Gaussian distribution at the lower end of the concentrations. Our results also highlight the difficulties in the establishment of clinically useful cutoffs. When we included all results from our reference samples, the 99th and 97.5th percentiles were 0.064 and 0.029 g/l, respectively. A look at the distribution graph, however, clearly indicated that these levels were governed by results not belonging to the distribution of the majority of results, which belonged to the Gaussian distribution. Therefore, we applied an outlier algorithm (19) , which eliminated all results exceeding 3ϫ the upper quartile level. After such correction, the 99th and 97.5th percentiles were 0.022 and 0.012 g/l, respectively, and it was quite apparent that the distribution of the results ROC curve analysis of the discrimination of healthy subjects and subjects with the acute coronary syndrome (GUSTO IV) with cTnT levels below (left) or above (right) 0.03 g/l. The ROC curve and 95% confidence interval are shown, as well as the sensitivities and specificities at the optimal discrimination levels of 0.0046 and 0.0164 g/l, respectively. Abbreviations as in Figures 1, 4 , and 6.
of the younger cohort, those Ͻ60 years of age, adapted to a harmonious Gaussian distribution, whereas the results of the older cohort still had a tail upward not included in the Gaussian distribution. In previous studies we showed that the application of the 99th percentile for the cohort of younger subjects actually identified more subjects at risk of premature death and/or MI (3, 7) . A similar approach in this study would mean a 99th percentile URL of 0.010 g/l, and as shown this was actually the case. The intriguing finding in this study, however, is that we found significant differences in event rates even at lower levels.
One of the most spectacular findings in this study was the large difference between the results of the healthy cohort and the results of the GUSTO IV cohort. These results indicate that the vast majority of subjects included in the GUSTO IV study had leakage of cTnI reflecting injury to the myocardium likely as a consequence of acute ischemia in most cases. One important question, therefore, is whether normal levels of cTnI, as measured by the hypersensitive Access cTnI assay, can be used to exclude, rule out, myocardial ischemia. The ROC curve analysis showed the optimal discrimination of health and disease at the level of 0.0064 g/l. At this level, the negative predictive value was 68.5%, but to achieve negative predictive values of more than 90% the cTnI levels should be below the median levels of the healthy subjects, that is, 0.0032 g/l. Indeed, below this level we had no adverse outcomes regarding death within 1 year or death/MI within 30 days among the GUSTO IV subjects. The above calculations were made on the assumption of accurate inclusions of all subjects among the healthy and diseased cohorts, which may not be the case. In a previous randomized clinical trial including patients with a clinical diagnosis of unstable angina, 14% of the patients included in the trial had no significant luminal diameter stenosis of a major coronary artery (20) , and in another ACS trial (21), 32% of those without detectable troponin T had no significant coronary stenosis. Hence, it is likely that a small proportion of patients included in the GUSTO IV trial had other causes of their chest pain at inclusion than true myocardial ischemia. Indeed, when we used cTnT levels as surrogate markers of non-ST-segment elevation MI and unstable angina, the distinction between MI and healthy subjects was very accurate, whereas the distinction between unstable angina and healthy subjects was less accurate, with sensitivities and specificities in the range of 75% to 80%. Therefore, further studies in carefully characterized patient materials are needed to establish the true sensitivity and specificity and to accurately define decision limits. However, the present results suggest that it might be possible to define such rule-out limits, and this would obviously have a very important impact on the clinical management of patients with suspected ACS. Slightly elevated levels of cTnI, however, are found, aside from ACS in many other disorders affecting the heart directly or indirectly (22, 23) . Therefore, in the future management of our patients with the aid of these hypersensitive cardiac troponin assays, we may need to define new decision limits and criteria for the diagnosis of acute ischemic diseases of the myocardium and for prediction of future events. The current consensus criteria suggest a rise and fall above the 99th percentile URL in cardiac troponins in addition to other symptoms and signs of ischemia as the diagnostic criteria for AMI (1) . With the hypersensitive cardiac troponin assays and with the lowering of the 99th percentile further, it is predicted that such changes will be seen much more frequently in patients without classical AMI caused by plaque rupture with a superimposed thrombus in the coronary arteries, and that this will prompt the clinician to be more active in defining the specific cause of the elevation in each case. Therefore, can we define criteria and decision limits that will guide the clinician to take appropriate action without jeopardizing the safety of our patients? When it comes to prediction, the situation seems slightly less complicated because this and other studies have shown that even minor elevations of cardiac troponins are associated with unfavorable long-term outcome and an increased risk of premature death and/or MI (3, 7, 8) . Thus, any elevations above the low 99th percentile are important signs, and the situation seems almost dichotomous. Highly sensitive troponin assays, therefore, might also be useful in the screening situation of populations at risk. With the current knowledge we may now adopt conventional criteria for the definition of what are normal or abnormal levels of cTnI, that is, use the 97.5th percentiles instead of the 99th percentiles because of the inherent difficulties of accurate definition of the latter. In addition to this, we may define levels below or above these levels to meet specific clinical needs, but as indicated previously, this will have to await further studies.
Conclusions
The hypersensitive cTnI assay from Beckman Coulter allows us to define normal plasma levels of cTnI. This information is novel and very important for our understanding of how to optimize the clinical utility of cTnI measurements in the diagnosis and outcome prediction of patients with cardiovascular disease. Our data also suggest that the hypersensitive cTnI assay may be a means to rule out patients with suspected ischemia of the myocardium and an unfavorable outcome.
